The project is implementing a SIOP PODC adapted treatment guideline for Wilms tumour in several centres in sub-Saharan Africa. This is done as a multi centre prospective clinical trial with uniform outcome evaluation. The project started in 2014. More than 300 patients have been included and treated.
End of treatment survival without evidence of disease increased from 52% to 68.5%. Death during treatment decreased from 21% to 13% and abandonment of treatment from 23% to 12%. Two year event free survival was 50% with abandonment of treatment considered as an event.
Please find the most recent publication about the project and this overall improved survival of children with Wilms tumour here
Please find a short video about the project and it’s impact here
To develop, implement and assess locally appropriate treatment guidelines and to reduce both abandonment of treatment and death during treatment to <10% in all our projects.
Children with common and curable cancers in sub -Saharan Africa will achieve survival rates greater than 60% in line with the vision of the WHO led Global Initiative for Childhood Cancer (GICC).
CANCaRe Africa aims to be an inclusive platform for multi-centre clinical research and care.
Currently there are three projects:
- The SIOP Africa / PODC Collaborative Wilms Tumour Project
- SUCCOUR – Supportive Care for Children with Cancer in Africa
- Towards Zero Percent Abandonment
THANK YOU TO OUR SPONSORS:
The Wilms tumour collaboration project is currently running in 8 centres in 5 sub-Saharan African countries. All participating centres have established Wilms tumour treatment. All participating centres have established Wilms tumour treatment.
A detailed treatment and study protocol was developed in March 2013 at a working group meeting in Malawi, following SIOP PODC guidelines. Collaborative Wilms Tumour Africa Treatment Guidelines Phase II are currently being updated, and will be launched in 2020.